Literature DB >> 32696070

Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts.

Adam Ciesiolka1, Anna Stroynowska-Czerwinska1,2, Paweł Joachimiak1, Agata Ciolak1, Emilia Kozlowska1, Michal Michalak1, Magdalena Dabrowska3, Marta Olejniczak3, Katarzyna D Raczynska4,5, Dominika Zielinska1, Magdalena Wozna-Wysocka1, Wlodzimierz J Krzyzosiak1, Agnieszka Fiszer6.   

Abstract

Polyglutamine (polyQ) diseases are incurable neurological disorders caused by CAG repeat expansion in the open reading frames (ORFs) of specific genes. This type of mutation in the HTT gene is responsible for Huntington's disease (HD). CAG repeat-targeting artificial miRNAs (art-miRNAs) were shown as attractive therapeutic approach for polyQ disorders as they caused allele-selective decrease in the level of mutant proteins. Here, using polyQ disease models, we aimed to demonstrate how miRNA-based gene expression regulation is dependent on target sequence features. We show that the silencing efficiency and selectivity of art-miRNAs is influenced by the localization of the CAG repeat tract within transcript and the specific sequence context. Furthermore, we aimed to reveal the events leading to downregulation of mutant polyQ proteins and found very rapid activation of translational repression and HTT transcript deadenylation. Slicer-activity of AGO2 was dispensable in this process, as determined in AGO2 knockout cells generated with CRISPR-Cas9 technology. We also showed highly allele-selective downregulation of huntingtin in human HD neural progenitors (NPs). Taken together, art-miRNA activity may serve as a model of the cooperative activity and targeting of ORF regions by endogenous miRNAs.

Entities:  

Keywords:  CAG repeats; Huntington’s disease; Polyglutamine diseases; Translational inhibition; miRNA

Year:  2020        PMID: 32696070     DOI: 10.1007/s00018-020-03596-7

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  95 in total

Review 1.  The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC.

Authors:  Marc R Fabian; Nahum Sonenberg
Journal:  Nat Struct Mol Biol       Date:  2012-06-05       Impact factor: 15.369

2.  Inhibition of translational initiation by Let-7 MicroRNA in human cells.

Authors:  Ramesh S Pillai; Suvendra N Bhattacharyya; Caroline G Artus; Tabea Zoller; Nicolas Cougot; Eugenia Basyuk; Edouard Bertrand; Witold Filipowicz
Journal:  Science       Date:  2005-08-04       Impact factor: 47.728

3.  Deadenylation is a widespread effect of miRNA regulation.

Authors:  Ana Eulalio; Eric Huntzinger; Tadashi Nishihara; Jan Rehwinkel; Maria Fauser; Elisa Izaurralde
Journal:  RNA       Date:  2008-11-24       Impact factor: 4.942

Review 4.  Towards a molecular understanding of microRNA-mediated gene silencing.

Authors:  Stefanie Jonas; Elisa Izaurralde
Journal:  Nat Rev Genet       Date:  2015-06-16       Impact factor: 53.242

5.  Estradiol receptor and cyclic nucleotide phosphodiesterase: functional relationship, possible role of guanine nucleotide binding proteins.

Authors:  R N Etingof; I L Dumler; M N Garnovskaja; S N Kalinina
Journal:  Biochem Int       Date:  1984-08

6.  Kinetic analysis reveals successive steps leading to miRNA-mediated silencing in mammalian cells.

Authors:  Julien Béthune; Caroline G Artus-Revel; Witold Filipowicz
Journal:  EMBO Rep       Date:  2012-06-08       Impact factor: 8.807

7.  miR-148 targets human DNMT3b protein coding region.

Authors:  Anja M Duursma; Martijn Kedde; Mariette Schrier; Carlos le Sage; Reuven Agami
Journal:  RNA       Date:  2008-03-26       Impact factor: 4.942

8.  The interactions of GW182 proteins with PABP and deadenylases are required for both translational repression and degradation of miRNA targets.

Authors:  Eric Huntzinger; Duygu Kuzuoglu-Öztürk; Joerg E Braun; Ana Eulalio; Lara Wohlbold; Elisa Izaurralde
Journal:  Nucleic Acids Res       Date:  2012-11-21       Impact factor: 16.971

Review 9.  The panorama of miRNA-mediated mechanisms in mammalian cells.

Authors:  Anna Stroynowska-Czerwinska; Agnieszka Fiszer; Wlodzimierz J Krzyzosiak
Journal:  Cell Mol Life Sci       Date:  2014-01-29       Impact factor: 9.261

10.  Translational repression and eIF4A2 activity are critical for microRNA-mediated gene regulation.

Authors:  H A Meijer; Y W Kong; W T Lu; A Wilczynska; R V Spriggs; S W Robinson; J D Godfrey; A E Willis; M Bushell
Journal:  Science       Date:  2013-04-05       Impact factor: 47.728

View more
  6 in total

1.  A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease.

Authors:  Anna Kotowska-Zimmer; Lukasz Przybyl; Marianna Pewinska; Joanna Suszynska-Zajczyk; Dorota Wronka; Maciej Figiel; Marta Olejniczak
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-05       Impact factor: 10.183

Review 2.  What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.

Authors:  Lukasz Przybyl; Magdalena Wozna-Wysocka; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

Review 3.  Implications of Poly(A) Tail Processing in Repeat Expansion Diseases.

Authors:  Paweł Joachimiak; Adam Ciesiołka; Grzegorz Figura; Agnieszka Fiszer
Journal:  Cells       Date:  2022-02-15       Impact factor: 6.600

4.  The Novel Role of hnRNP UL1 in Human Cell Nucleoli.

Authors:  Marlena Cichocka; Anna Karlik; Patrycja Plewka; Kishor Gawade; Agata Stępień; Patrycja Świergiel; Ankur Gadgil; Katarzyna Dorota Raczyńska
Journal:  Int J Biol Sci       Date:  2022-07-18       Impact factor: 10.750

Review 5.  Emerging Therapies for Huntington's Disease - Focus on N-Terminal Huntingtin and Huntingtin Exon 1.

Authors:  M Leontien van der Bent; Melvin M Evers; Astrid Vallès
Journal:  Biologics       Date:  2022-09-30

Review 6.  Regulatory Potential of Competing Endogenous RNAs in Myotonic Dystrophies.

Authors:  Edyta Koscianska; Emilia Kozlowska; Agnieszka Fiszer
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.